As reported earlier this week, the US Food and Drug Administration (FDA) continued to crackdown on overseas manufacturing plants last fiscal year with a 40 per cent increase in warning letters.
Sites in Mexico and India accounted for one-third of overseas production plants cited in FDA cGMP (current good manufacturing practice) warning letters last year. The map below shows the sites of these production plants and every other facility named by the FDA in fiscal 2011 warning letters.
North America and Western Europe account for many of the warning letters. For the first time since 2009 the FDA sent no warning letters to facilities in South America, leaving India and China as the emerging market hotbeds of regulatory enforcement actions.